Chicago: Interest in PyroGluAβ Flares Up in Academia
Pyroglutamate Aβ has been making a return to center stage in AD research after languishing in relative obscurity for a decade following its initial discovery...
1378 RESULTS
Sort By:
Pyroglutamate Aβ has been making a return to center stage in AD research after languishing in relative obscurity for a decade following its initial discovery...
At long last, drug developers' efforts in developing β-secretase (BACE1) inhibitors are starting to pay off...
Researchers called the first in-person gathering of a newly formed working group on posterior cortical atrophy (PCA)...
As to precisely where the hippocampus starts and stops on a magnetic resonance image, researchers have little consensus...
To no one’s surprise, C9ORF72 occupied center stage at the 8th International Conference on Frontotemporal Dementias, held 5-7 September in Manchester...
Researchers found that in cases of ALS due to FUS mutations, and FTLD linked to FUS proteinopathy, the cellular mechanisms of disease are somewhat distinct...
NeuroPhage Pharmaceuticals, a small startup company, is banking that viral capsids will break up aggregates of Aβ and other amyloidogenic proteins...
Researchers, therapists, patients, and caretakers came together in Chicago, Illinois, to share a common goal of finding a cure for ALS...
The buzz that 2,711 scientists from 68 countries generated at AD/PD 2011 was remarkable for how it sounded opposing notes at equal volume...
The 5th HAI conference concluded with a panel discussion of how far amyloid PET has come in the seven years since its first major publication...
Finding Aβ oligomers bound to cellular prion (PrPc) was absolutely unexpected...
This second meeting report is continued from <a href="/news/conference-coverage/conformation-rules-part-1-news-common-threads-debate-san-diego-conference">Part 1</a>...
At the l7th Annual Marian S. Ware Neurodegenerative Diseases Research Retreat, hosts Virginia Lee and John Trojanowski pulled together a formidable roster of speakers...
Researchers announced the selection of solanezumab as the first therapeutic drug to be evaluated in the A4 prevention clinical trial...
Over the past year, chatter has been building about combination drug therapy as the "New New Thing" in Alzheimer’s disease research...